# The Role of Glycolysis in Tumorigenesis—The Many Unresolved Issues

**Authors:** Fabrizio Marcucci, Shibo Wei, Marco Cordani

PMC · DOI: 10.3390/cells15060499 · 2026-03-11

## TL;DR

This paper explores how glycolysis contributes to cancer development and highlights unresolved questions about its role in tumor metabolism and non-metabolic functions.

## Contribution

The paper proposes tentative answers to unresolved questions about glycolysis in tumors, aiming to guide future research.

## Key findings

- Fermentative glycolysis supports multiple functions in tumors, including energy production and biomass generation.
- Moonlighting functions of glycolysis are not fully understood and may exist in non-transformed cells as well.
- The regulation and selective activation of glycolytic functions vary across tumor types and stages.

## Abstract

The upregulation of glycolysis and resultant lactate production (hereafter referred to as fermentative glycolysis) even under normoxic conditions has been considered a hallmark of cancer. In recent years, however, it has become clear that fermentative glycolysis in tumors is not as all-inclusive as originally thought. Nevertheless, many tumor types at different stages of progression are characterized by a predominantly glycolytic metabolism. Fermentative glycolysis in tumors supports several different functions: energy production in the form of adenosine triphosphate molecules, the maintenance and amplification of glycolytic metabolism itself, the feeding of oxidative metabolism through the production of lactate, the generation of metabolic intermediates for biomass production, and the execution of non-metabolic, non-canonical, so-called moonlighting functions. This knowledge, however, raises a number of different questions which, by and large, are still unanswered today. Are there different degrees of glycolysis upregulation in order to support the different functions? How is fermentative glycolysis maintained even under normoxic conditions? Why do moonlighting functions exist, given that they are unrelated to the metabolic steps of glycolysis? Moonlighting functions are generally discussed in the context of tumorigenesis, but do they exist also in non-transformed cells? Do they occur in a coordinated manner in all tumor cells or are they activated selectively depending on the tumor type, tumor stage, or on the inducing stimulus? While these issues are mostly unresolved, in this article we propose some tentative answers which, we hope, may promote new research directions which may further our understanding in this field.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** PDK1 (pyruvate dehydrogenase kinase 1) [NCBI Gene 5163], CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, Kat2a (K(lysine) acetyltransferase 2A) [NCBI Gene 14534] {aka 1110051E14Rik, Gcn5, Gcn5l2, mmGCN5}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, GPR132 (G protein-coupled receptor 132) [NCBI Gene 29933] {aka G2A}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, SLC16A3 (solute carrier family 16 member 3) [NCBI Gene 9123] {aka MCT 3, MCT 4, MCT-3, MCT-4, MCT3, MCT4}, REL (REL proto-oncogene, NF-kB subunit) [NCBI Gene 5966] {aka C-Rel, HIVEN86A, IMD92}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, Dnmt1 (DNA methyltransferase 1) [NCBI Gene 13433] {aka Cxxc9, Dnmt, Dnmt1o, MCMT, MTase, Met-1}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, H3c7 (H3 clustered histone 7) [NCBI Gene 260423] {aka H3.2-221, H3c13, H3c14, H3c15, H3c2, H3c3}, PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) [NCBI Gene 5209] {aka IPFK2, PFK2, iPFK-2}, LPAR2 (lysophosphatidic acid receptor 2) [NCBI Gene 9170] {aka EDG-4, EDG4, LPA-2, LPA2}, BATF (basic leucine zipper ATF-like transcription factor) [NCBI Gene 10538] {aka B-ATF, BATF1, SFA-2, SFA2}, SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, IRF4 (interferon regulatory factor 4) [NCBI Gene 3662] {aka IMD131, LSIRF, MUM1, NF-EM5, SHEP8}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, CD47 (CD47 molecule) [NCBI Gene 961] {aka IAP, MER6, OA3}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}
- **Diseases:** tumorigenicity (MESH:D002471), non-small cell lung cancer (MESH:D002289), toxicity (MESH:D064420), colorectal carcinoma (MESH:D015179), mitochondrial dysfunction (MESH:D028361), injury to (MESH:D014947), acidosis (MESH:D000138), triple-negative breast cancer (MESH:D064726), leukemic (MESH:D007938), tumorigenesis (MESH:D063646), bacterial infections (MESH:D001424), lymphoma (MESH:D008223), inflammatory (MESH:D007249), neuroblastoma (MESH:D009447), lactic acidosis (MESH:D000140), lactate (MESH:D007775), melanoma (MESH:D008545), Tumor (MESH:D009369), GBM (MESH:D005909), hypoxia (MESH:D000860)
- **Chemicals:** lipids (MESH:D008055), pentose phosphate (MESH:D010428), hyaluronan (MESH:D006820), triglycerides (MESH:D014280), glycerol (MESH:D005990), glyceraldehyde 3-phosphate (MESH:D005986), 13C-glucose (-), cholesterol (MESH:D002784), 2-deoxy-D-glucose (MESH:D003847), superoxide (MESH:D013481), glutamine (MESH:D005973), acids (MESH:D000143), oxygen (MESH:D010100), Lactate (MESH:D019344), carbon (MESH:D002244), TCA (MESH:D014233), Fatty acids (MESH:D005227), metformin (MESH:D008687), CO2 (MESH:D002245), vitamin D. (MESH:D014807), ATP (MESH:D000255), lipopolysaccharide (MESH:D008070), steroid hormones (MESH:D013256), flavin adenine dinucleotide (MESH:D005182), CoA (MESH:D000105), Pyruvate (MESH:D019289), IACS-010759 (MESH:C000710313), acetate (MESH:D000085), Glucose (MESH:D005947), PEP (MESH:D010728), AZD3965 (MESH:C000592351), proton (MESH:D011522), ROS (MESH:D017382), NAD+ (MESH:D009243), isoleucine (MESH:D007532), ribose phosphate (MESH:C031626), coenzyme A (MESH:D003065), alpha-ketoglutarate (MESH:D007656), phospholipids (MESH:D010743), glycogen (MESH:D006003), bile salts (MESH:D001647), amino acid (MESH:D000596), H2O2 (MESH:D006861), purines (MESH:D011687)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** BRAFV600E
- **Cell lines:** C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025559/full.md

---
Source: https://tomesphere.com/paper/PMC13025559